Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

NCT03085810 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1225

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated earlier as the study sponsor collected sufficient data to perform all analyses as per pre-specified endpoints in the study protocol.

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Ocrelizumab

Sponsor

Hoffmann-La Roche